The FDA has granted full approval to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
Due to possible cardiac toxicity during Herceptin and pertuzumab treatment in HER2+BC, patient cardiac function is monitored via:
Patients with NHL with intermediate risk for FN maintain that risk even with pegfilgrastim prophylaxis, according to research presented at the NCCN Annual Conference.
Findings from a study presented at the NCCN Virtual Annual Congress found that regular DBHI for RNI-rBC improved lung and liver parameters.
Tucatinib plus letrozole and palbociclib was well-tolerated and active in patients with HR and HER2-positive metastatic breast cancer, according to interim data presented at the SABCS Annual Meeting.
IPATunity130 trial data showed that adding ipatasertib to paclitaxel did not improve PFS in patients with PIK3CA/AKT1/PTEN-altered TNBC.
True or false: Paclitaxel improved PFS and OS compared to capivasertib plus paclitaxel for metastatic triple-negative breast cancer.
True or false: PIK3CA mutations in breast cancer are not accurately detected using ctDNA versus tumor tissue.
The FDA has approved pembrolizumab combined with chemo for the treatment of locally recurrent unresectable or metastatic TNBC.